Filter by Year:

July 21, 2026

Ascidian Therapeutics Announces Leadership Transition

June 3, 2026

Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

May 4, 2026

Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans

April 28, 2026

Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting

January 7, 2026

Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease

June 24, 2025

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease

May 6, 2025

Ascidian Therapeutics Announces Formation of Scientific Advisory Board

September 27, 2024

Ascidian Therapeutics Named to 2024 “Endpoints 11” List of Most Promising Biotechs

August 13, 2024

Ascidian Therapeutics Strengthens Leadership Team

August 5, 2024

Fierce Biotech Names Ascidian Therapeutics a “Fierce 15” Biotech Company of 2024